Exhibits
10-K
from 10-K 171 pages 10-K
03/18/25
EX-1.1
from 10-K 39 pages Olema Pharmaceuticals, Inc. $100,000,000 Common Stock Sales Agreement
03/18/25
EX-10.14
from 10-K 27 pages Olema Pharmaceuticals, Inc. 2022 Inducement Plan Adopted by the Board of Directors: January 19, 2022 Amended by the Compensation Committee of the Board of Directors: December 5, 2024 Effective: January 1, 2025
03/18/25
EX-10.18
from 10-K 10 pages January 27, 2025 Shawnte Mitchell Email/Docusign Re: Employment Terms 1
03/18/25
EX-10.25
from 10-K 63 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Information That Was Omitted Has Been Noted in This Document With a Placeholder Identified by the Mark “[***]”. Clinical Trial Collaboration and Supply Agreement
03/18/25
EX-10.26
from 10-K 3 pages Amendment Number No. 1 to Drug Discovery Collaboration and License Agreement
03/18/25
EX-10.27
from 10-K 3 pages Amendment Number No. 2 to Drug Discovery Collaboration and License Agreement
03/18/25
EX-19.1
from 10-K 16 pages Report furnished to security holders
03/18/25
EX-21.1
from 10-K 2 pages Subsidiaries of the registrant
03/18/25
EX-23.1
from 10-K 2 pages Consent of expert or counsel
03/18/25
EX-31.1
from 10-K 2 pages Management certification of annual or quarterly disclosure
03/18/25
EX-31.2
from 10-K 2 pages Management certification of annual or quarterly disclosure
03/18/25
EX-32.1
from 10-K 2 pages Management certification of financial report
03/18/25
EX-32.2
from 10-K 2 pages Management certification of financial report
03/18/25
EX-97.1
from 10-K 7 pages  
03/18/25
Graphics & Data Files
External Links